• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

European advisory committee backs label update for Nordisk’s Tresiba

March 24, 2017 By Sarah Faulkner

European advisory committee backs label update for Nordisk's TresibaShares in Novo Nordisk (NYSE:NVO) were up 2% this morning after the European Medicines Agency’s Committee for Medicinal Products for Human Use backed the company’s application for a label update to its Tresiba insulin injection.

The company submitted an application in November to add data from 2 studies to the medication’s label. The final ruling is expected to come from the committee in 60 days.

Nordisk requested that data from trials Switch I and Switch II be included on Tresiba’s label. In the Switch I study, patients with Type I diabetes who received Tresiba in combination with insulin aspart had 11% fewer hypoglycemic episodes that those receiving insulin glargine and insulin aspart. They also experienced 36% fewer episodes of nocturnal hypoglycemia and 35% fewer episodes of severe hypoglycemia than their counterparts.

In the Switch II study, patients with Type II diabetes that were treated with Tresiba and oral antidiabetic drugs had fewer episodes of hypoglycemia, and nocturnal hypoglycemia compared to patients who received insulin glargine and oral antidiabetic drugs.

Both studies also reportedly demonstrated that Tresiba was non-inferior to insulin glargine according to blood glucose level reduction.

In November, Nordisk said that data from the Devote clinical trial indicated that its injected insulin, Tresiba, reduced the risk of severe hypoglycemia when compared to insulin glargine.

The trial enrolled more than 7,500 Type II diabetes patients at high risk of adverse cardiovascular events and treated them for 2 years with either Tresiba or insulin glargine U100. The long term analysis sought to confirm interim data that the Denmark-based company used to support its FDA approval for Tresiba in September last year.

The Devote trial met its primary endpoint, demonstrating non-inferiority of major adverse cardiovascular events with the injected insulin degludec compared to insulin glargine. There was no statistical difference between the 2 treatments and their safety profiles, the company reported.

Filed Under: Clinical Trials, Diabetes, Featured, Regulatory/Compliance Tagged With: Novo Nordisk

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS